ReviewThe international journal of neuropsychopharmacology2017
Dopamine System Dysregulation in Major Depressive Disorders.
Review in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05487885 (Anhedonia, Development, and Emotions), which is not on this map. Cited by 370 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (ADEPT) Study
Who cites it
370 citing papers in PubMed, 7 syntheses or guidelines pooled it, 723 citations in OpenAlex.
- Nitrous oxide for the treatment of depression: a systematic review and meta-analysis.EBioMedicine · 2025Pooled it
- Efficacy and Safety of Neuromodulation Techniques in Depression Treatment: A Systematic Review and Meta-Analysis.Psychiatry and clinical psychopharmacology · 2025Pooled it
- Metabolomics in Depression: What We Learn from Preclinical and Clinical Evidences.Molecular neurobiology · 2025Pooled it
- The role of the amygdala in depression: a bibliometric analysis (2015-2024).Frontiers in psychiatry · 2025Pooled it
- Associations of anxiety and depression with restless leg syndrome: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Adaptogens on Depression-Related Outcomes: A Systematic Integrative Review and Rationale of Synergism with Physical Activity.International journal of environmental research and public health · 2023Pooled it
- Agomelatine as adjunctive therapy with SSRIs or SNRIs for major depressive disorder: a multicentre, double-blind, randomized, placebo-controlled trial.BMC medicine · 2025Trial
- Embodied cognition driven Qigong: a cross-sectional study and a pilot randomized controlled trial on managing depression and preventing relapse in substance dependence.Frontiers in public health · 2024Trial
- A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.Translational psychiatry · 2023Trial
- Electrophysiological evidence of mal-adaptation to error in remitted depression.Biological psychology · 2023Trial
- The catecholamine precursor Tyrosine reduces autonomic arousal and decreases decision thresholds in reinforcement learning and temporal discounting.PLoS computational biology · 2022Trial
- Transcutaneous auricular vagus nerve stimulation for anxiety symptoms across fear, trauma, and disease contexts: a narrative review of clinical evidence and mechanisms.European archives of psychiatry and clinical neuroscience · 2026Review
- Is cold exposure a viable lifestyle intervention for mental health? Reviewing evidence and mechanisms.Molecular psychiatry · 2026Review
- Voluntary Exercise and Hippocampal Memory Enhancement: Decoding the Molecular Blueprint.Journal of molecular neuroscience : MN · 2026Review
- Biological factors contributing to divergent cortical abnormalities in adolescent and adult psychiatric disorders.Translational psychiatry · 2026Article
- The ventral/anterior hippocampus as a central hub for stress-related dopaminergic circuit dysfunction in psychiatric disorders.Molecular psychiatry · 2026Review
- Neurochemical drivers of effort: The roles of dopamine and beyond in physical and cognitive exertion.Neuroscience and biobehavioral reviews · 2026Review
- Radiomic Signature of the Substantia Nigra on Neuromelanin-Sensitive MRI Distinguishes Bipolar II Disorder From Unipolar Depression.Brain and behavior · 2026Article
- Association Between Self-Reported Pornographic Consumption Habits and Anxiety and Depression: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
310 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Anhedonia is considered a core feature of major depressive disorder, and the dopamine system plays a pivotal role in the hedonic deficits described in this disorder. Dopaminergic activity is complex and under the regulation of multiple brain structures, including the ventral subiculum of the hippocampus and the basolateral amygdala. Whereas basic and clinical studies demonstrate deficits of the dopaminergic system in depression, the origin of these deficits likely lies in dysregulation of its regulatory afferent circuits. This review explores the current information regarding the afferent modulation of the dopaminergic system and its relevance to major depressive disorder, as well as some of the system-level effects of novel antidepressants such as agomelatine and ketamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.